Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden

Table 2 Model transition probabilities by GOLD states

Usual care	First cycle			Subsequent treatment cycles
	TO			TO
	GOLD II	GOLD III	GOLD IV	GOLD II	GOLD III	GOLD IV
FROM
GOLD II	0.86	0.13	0.01	0.91	0.09	0.00
GOLD III	0.13	0.81	0.06	0.08	0.88	0.04
GOLD IV	0.02	0.22	0.76	0.00	0.13	0.87

Tiotropium/glycopyrronium	First cycle			Subsequent treatment cycles
	TO			TO
	GOLD II	GOLD III	GOLD IV	GOLD II	GOLD III	GOLD IV
FROM
GOLD II	0.92	0.08	0.00	0.92	0.08	0.00
GOLD III	0.17	0.80	0.03	0.08	0.88	0.04
GOLD IV	0.03	0.28	0.69	0.00	0.12	0.88

Source: [28] (derived from [17]). For tiotropium and glycopyrronium cohorts, usual care probabilities were assumed to hold when off treatment. Probabilities have been recalculated to reflect three month probabilities. Death has been excluded, as this model carries separate mortality rates derived for a Swedish population

ISSN: 1478-7547